Condition: PNH - Paroxysmal Nocturnal Hemoglobinuria · Sponsor: Shanghai Lanyi Therapeutics Co., Ltd.
This is a multicenter, open-label, Phase Ib clinical trial designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of the humanized monoclonal antibody EA5 in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
This description comes directly from the study's public registry record.
Fengkui zhang, Dr. · +86-022-23909999 · zhfk@hotmail.com
Always discuss trial participation with your own doctor first.
| The Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) | Tianjin, Tianjin Municipality, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine, Chengzhan Campus | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07256301